S(+) desmethylselegiline and its use to treat narcolepsy
View Patent ↗The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
1. A method of treating narcolepsy in a subject comprising administering to the subject suffering from narcolepsy S(+)-desmethylselegiline or a pharmaceutically acceptable salt thereof, employing a single or multiple dosage regimen effective to treat the narcolepsy.
2. The method of claim 1 , wherein the subject is human.
3. The method of claim 1 , wherein the S(+)-desmethylselegiline is in a substantially isomerically pure form.
4. The method of claim 1 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered orally.
5. The method of claim 1 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered non-orally.
6. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered transdermally.
7. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered parenterally.
8. The method of claim 1 , wherein the dosage regimen of S(+)-desmethylselegiline administered to the subject per day is at least about 0.015 mg/kg of the subject's body weight, calculated on the basis of the free secondary amine.
9. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered buccally.
10. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered sublingually.
11. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered intravenously.
12. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered subcutaneously.
13. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered rectally.
14. The method of claim 5 , wherein the S(+)-desmethylselegiline or a pharmaceutically acceptable acid addition salt thereof is administered intra-peritoneally.
15. The method of claim 1 , wherein the dosage regimen of S(+)-desmethylselegiline administered to the subject per day is at least about 0.10 mg/kg of the subject's body weight, calculated on the basis of the free secondary amine.
16. The method of claim 1 , wherein the dosage regimen of S(+)-desmethylselegiline administered to the subject per day is at least about 1.0 mg/kg of the subject's body weight, calculated on the basis of the free secondary amine.
17. The method of claim 1 , wherein the single dosage regimen is employed.
18. The method of claim 1 , wherein the multiple dosage regimen is employed.